SYD985 TREATMENT OF T-DM1 REFRACTORY CANCER PATIENTS

The present invention relates to the duocarmycin-containing antibody-drug conjugate (ADC) trastuzumab vc-seco-DUBA (SYD985) for use in the treatment of trastuzumab emtansine (T- DM1) refractory HER2 IHC 3+ or HER2 IHC 2+/FISH positive cancer patients, particularly T-DMI refractory breast cancer pati...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	KOPER, NORBERT PETER, VOORTMAN, GERRIT
Format:	Patent
Sprache:	eng
Schlagworte:	HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The present invention relates to the duocarmycin-containing antibody-drug conjugate (ADC) trastuzumab vc-seco-DUBA (SYD985) for use in the treatment of trastuzumab emtansine (T- DM1) refractory HER2 IHC 3+ or HER2 IHC 2+/FISH positive cancer patients, particularly T-DMI refractory breast cancer patients.